Beckley Psytech vs BioNTech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Beckley Psytech (now AtaiBeckley) achieved FDA Breakthrough Therapy Designation for BPL-003 (5-MeO-DMT nasal spray) for treatment-resistant depression in October 2025; Phase 3 trial initiation planned Q2 2026.
About
Beckley Psytech is a UK-based clinical-stage biotechnology company developing psychedelic-derived medicines for neuropsychiatric disorders, with a primary focus on treatment-resistant depression (TRD). Its lead asset, BPL-003, is an intranasal formulation of 5-MeO-DMT (mebufotenin benzoate) designed to deliver a controlled, short-duration psychedelic experience under medical supervision. In July 2025, Beckley Psytech and its partner atai Life Sciences reported positive topline results from a Phase 2b trial of BPL-003, with a single 8mg dose achieving a 12.1-point reduction on standardized depression scales at day 29 — a clinically meaningful outcome.
German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease;
About
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.